Jasper Therapeutics merges with Kira Pharmaceuticals
Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals, forming a combined Nasdaq-listed company under ticker JSPR. The deal includes a $132M private placement and a $12M Mirador out-licensing payment on signing, funding operations through H2 2028. Pipeline includes KP-104, briquilimab, and KP-701 with upcoming clinical milestones.
How this was made
The 30-second read
Why it matters
The transaction is paired with a $132M private placement and a Mirador out-licensing agreement (with $12M upon signing), extending funding through 2H 2028 while broadening the combined pipeline across complement inhibition and immunology antibodies.
Market read
Traders can reassess dilution and runway risk, and position for upcoming clinical and FDA milestone catalysts tied to the combined pipeline.
What to watch
No acquisition consideration details, no updated valuation metrics, and no timeline certainty for FDA meetings or clinical readouts are provided, which can drive post-news volatility.
Background
Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals, creating a combined biologics-focused company in immunologically driven conditions.
Ticker impact
Jasper completed an all-stock acquisition of Kira and will trade on Nasdaq under JSPR, funding operations via a $132M private placement.
Likely positive medium-term bias on deal completion and cash runway, with volatility around integration and upcoming clinical milestones.
The article discloses a completed all-stock acquisition, a sizable private placement, and specific pipeline milestone expectations (KP-104, briquilimab, KP-701), which can re-rate risk and valuation, but no exchange ratio or immediate clinical readout is provided.
Market effects
Reinforces consolidation in immunology/complement drug development and highlights continued investor appetite for biologics pipeline build-outs.
Primarily US biotech sentiment via Nasdaq trading and US FDA milestone planning.
Limited direct global read-through beyond complement and immunology therapeutic interest.
Counterpoint
The all-stock structure can dilute existing holders, and the pipeline milestones are multi-year, so near-term fundamentals may not improve immediately.
Key entities
- public_companyJasper Therapeutics
Nasdaq-listed acquirer that completed the all-stock acquisition and will trade under JSPR.
- public_companyKira Pharmaceuticals
Target whose complement portfolio and candidates (KP-104, briquilimab, KP-701) are folded into the combined pipeline.
- private_or_otherMirador Therapeutics
Partner in an out-licensing agreement tied to KP-301 and KP-402, including $12M upon signing.
- investorAffinity Asset Advisors
Co-lead on the $132M private placement financing.
- investorIkarian Capital
Co-lead on the $132M private placement financing.
